Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 3/20 | 0.56 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.48 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.48 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.45 |
| ▸ | POLM | Q9NP87 | 2/20 | 0.44 |
| ▸ | POLK | Q9UBT6 | 2/20 | 0.44 |
| ▸ | POLL | Q9UGP5 | 2/20 | 0.44 |
| ▸ | POLH | Q9Y253 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5919579 | 0.81 | KCNA3 (0.50) | TXNRD1TXNRD3TXNRD2CYP3A4CYP2A6 | |
| SCHEMBL30574283 | 0.78 | TOP1 (0.66) | TOP1CYP3A4CYP2A6PTPRCPOLM | |
| SCHEMBL24194098 | 0.78 | TOP1 (0.66) | TOP1CYP3A4CYP2A6PTPRCPOLM | |
| SCHEMBL3434411 | 0.77 | CYP3A4 (0.49) | TXNRD1TXNRD3TXNRD2CYP3A4CYP2A6 | |
| SCHEMBL10663882 | 0.77 | KCNA3 (0.57) | TXNRD1TXNRD3TXNRD2CYP3A4CYP2A6 | |
| SCHEMBL3435349 | 0.76 | CYP3A4 (0.44) | TXNRD1TXNRD3TXNRD2CYP3A4CYP2A6 | |
| SCHEMBL20454563 | 0.76 | HPGD (0.47) | CYP3A4CYP2A6PTPRCHPGDMAPK1 | |
| Juglone SCHEMBL8903905 | 0.75 | MAPT (0.67) | TOP1TXNRD1TXNRD3TXNRD2CYP3A4 | |
| SCHEMBL29771458 | 0.75 | PTPRC (0.57) | CYP3A4CYP2A6PTPRCHPGDMAPK1 | |
| SCHEMBL24194430 | 0.74 | POLM (0.60) | TOP1CYP3A4POLMPOLKPOLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113368087-A | Juglone derivatives and application thereof in preparation of drugs for treating brain tumors through chemotherapy | 复旦大学附属华山医院 | 2021-09-10 | — | — | CN | claimed |
| CN-113368087-A | Juglone derivatives and application thereof in preparation of drugs for treating brain tumors through chemotherapy | 复旦大学附属华山医院 | 2021-09-10 | — | — | CN | disclosed |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS | 2019-06-06 | — | — | US | disclosed |
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-3191087-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | Pellficure Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040896-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | TOP1 219/4885TXNRD1 543/4885TXNRD3 332/4885 |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | TOP1 219/4885TXNRD1 543/4885TXNRD3 332/4885 |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | TOP1 219/4885TXNRD1 543/4885TXNRD3 332/4885 |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | TOP1 219/4885TXNRD1 543/4885TXNRD3 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.